medigraphic.com
ISSN 0016-3813 (Impreso)

2003, Número 2

<< Anterior Siguiente >>

Gac Med Mex 2003; 139 (2)


Linfomas No Hodgkin. estado actual

I. Introducción
II. Clasificación de los linfomas, viabilidad de la clasificación molecular
III. Nuevas estrategias terapéuticas en los linfomas. ¿Ha cambiado el panorama de los linfomas en la última década?

Figueroa F, Silva-Moreno M, Rivas-Vera S, Sobrerilla P

Idioma: Español
Referencias bibliográficas: 25
Paginas: 139-147
Archivo PDF: 80.42 Kb.


FRAGMENTO

En este simposium participáran connotados especialistas de México y Canada, abordaremos temas de candente actualidad, como la biología molécular en los linfomas y desde luego sin quedarse atrás las estrategias de manejo en la enfermedad de Hodgkin y en los Linfomas, en este orden haremos el desglose de la introducción.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Beutz M,Trumper I. Workshop report: Genetics and immunology of aggresive NHL. Ann Hematol 2001;8(Suppl 3):B 5-7.

  2. Ohno H, Ueda C, Akasaka T. The T (9,14) (p13,q32) translocation in B cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 2000;36:435-445.

  3. Registro Histopatologico de Neoplasias Malignas en México, Dirección General de Epidemiologia, Secretaria de Salud, México 1996.

  4. Ekstrand BC, Horning SJ. Hodgkin's disease. Blood Reviews 2002;16:111-117.

  5. MauchPM, Duhmke E, Connors J, Pavlosky S. Treatmente of favorable prognosis stage I-II Hodgkin's Disease in Hodgkin's Disease eds Mauch PM,Armitage J, Diehl V,Hoppe R,Weiss L(Lippincott-Raven Philadelphia,PA 1999)pp 435-458.

  6. Yahalom J, Mauch PM. Early Stage Hodgkin's Disease.44th Annual Meeting Course 207 of ASTRO October 6-10 2002.New Orleans.

  7. Gospodarowics MK,Sutcliffe SB,Clark RM et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin;s disease treated with radiation alone.Int J. Radiat Oncol Biol Phys 1992;22:859.

  8. Linch DC, Gosden RG, tulandi T, Tan SL, HancocK SL. Hodgkin's Lymphoma: Choice of therapy and late complications Education Program Book.american Society of Hematology 2000.San Francisco Cal 205-21.

  9. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.

  10. Coiffier B, Lepage E, Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.

  11. Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131 Iodine Mab LL2 ( CD22) in patients with recurrent Non-Hodgkin's Lymphoma. Leukemia and Lymphoma 2000;38(1-2):91-101.

  12. White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B cell lymphoma with yttrium 90 anti idiotype monoclonal antibodies. Blood 1996;87:3640-3649.

  13. Brousse N. Histological classification of non-Hodgkin’s lymphomas. in Non-Hodgkin’s lymphomas edited by: Solal-Céligny P, Brousse N, Reyes F, Gissselbrecht C and Coiffier B; Editions Frison-Roche Paris 1993 pages: 95-100.

  14. Jaffe ES, Harris NL, Chan JKC et al. Proposed World Health Organization classification of neoplastic diseases of hematopoietic and lymphoid tissue. Am J Surg Pathol 1997;21:114-21

  15. Harris NL, Jaffe ES, Diebold J et al. Lymphoma classification –from controversy to consensus: The REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 2000;11(supl1):3-10.

  16. Jaffe ES, Harris NL, Stein H and Varian JW. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press. Lyon, France, 2001.

  17. Macintyre E, Willerford D, Morris SW. Non-Hodgkin’s lymphoma: Molecular Features of B Cell lymphoma. En American Society of Hematology. Education Program Book. Schechter GP, Berliner N, Telen MJ, Bajus JL (Eds.) San Francisco, Cal. 2000. pp 180-203.

  18. Harris NL, Stein H, Coupland S et al. New approaches to lymphoma diagnosis. En American Society of Hematology. Education Program Book. Schechter GP, Broudy VC, Williams ME, Bajus JL (Eds.) Orlando FL. 2001 pp. 194-220.

  19. 1· Armitage JO: Treatment of Non-Hodgkin Lymphoma. N Engl J Med 1993; 328:1023-1030.

  20. 2· Coiffer B, Lepage E, Brière J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B cell lymphoma. N Engl J Med 2002; 346:235-42.

  21. 3· Horning SH, Glick JH, Kim K et al: Final report of E1384: CHOP versus CHOP

  22. 4· Marcus R, Hasgenbeek A, Eghbali H et al: Fludarabine versus CVP in newly diagnosed patients with stages III/IV non-Hodkin’s lymphoma. Final analysis of prospective randomized phase III intergroup study. Ann Oncol 2002; 13(Suppl.2):181

  23. 5· McLaughin P, Grillo-López AJ, Link BK et al: Rituximab chimerie anti CD-20 monoclonal antibody therapy for relapsed indolent lymphoma; half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16:2825-33.

  24. 6· Miller TP, Leblanc M, Spier C et al: CHOP alone compared to CHOP plus radiotherapyfor early stage aggressive non-Hodgkin´s lymphoma; update of the Southewest oncology Group randomized trial. Program and abstracts of the 43rd Annual Meeting of the American Society of Hematology; December 711, 2001, Orlando, Florida. Abstract 3024

  25. 7· Pfreundschuh M, Trümper L, Kloess M et al: Two-weekly CHOP (CHOP-14): new standar regimen for patients withaggressive non-Hodgkin’slymphoma (NHL). Ann Oncol 2002; 13 (Suuppl.2) 81 (Abstr)




2020     |     www.medigraphic.com